Published in Radiother Oncol on September 07, 2006
Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol (2010) 1.32
Analysis of inter-fraction setup errors and organ motion by daily kilovoltage cone beam computed tomography in intensity modulated radiotherapy of prostate cancer. Radiat Oncol (2012) 0.91
Effect of constipation on dosimetry after permanent seed brachytherapy for prostate cancer. J Contemp Brachytherapy (2015) 0.89
Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only? Radiat Oncol (2008) 0.86
Random variation in rectal position during radiotherapy for prostate cancer is two to three times greater than that predicted from prostate motion. Br J Radiol (2014) 0.84
Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol (2007) 0.83
Variability in bladder volumes of full bladders in definitive radiotherapy for cases of localized prostate cancer. Strahlenther Onkol (2010) 0.81
Prostate image-guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol (2011) 0.78
Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br J Radiol (2014) 0.78
Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer. Radiat Oncol J (2016) 0.75
Potential risk of alpha-glucosidase inhibitor administration in prostate cancer external radiotherapy by exceptional rectal gas production: a case report. J Med Case Rep (2014) 0.75
Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment. Br J Radiol (2015) 0.75
Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications. Radiat Oncol (2016) 0.75
[Radiotherapy for prostate cancer]. Wien Med Wochenschr (2007) 0.75
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07
Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol (2013) 2.84
miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52
Does tumor growth follow a "universal law"? J Theor Biol (2003) 2.47
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47
Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol (2012) 2.46
Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol (2005) 2.14
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int (2010) 2.08
Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys (2003) 1.88
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol (2009) 1.51
Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol (2006) 1.45
Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? BJU Int (2014) 1.44
Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys (2004) 1.43
Cancer of the prostate. Crit Rev Oncol Hematol (2005) 1.31
IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol (2009) 1.27
Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys (2007) 1.23
Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys (2008) 1.21
Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol (2008) 1.20
LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Natl Acad Sci U S A (2004) 1.20
Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys (2007) 1.17
Dosimetric characterization and use of GAFCHROMIC EBT3 film for IMRT dose verification. J Appl Clin Med Phys (2013) 1.16
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol (2011) 1.16
Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys (2003) 1.13
The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int (2012) 1.11
Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis. J Clin Microbiol (2006) 1.10
Quality indicators in radiotherapy. Radiother Oncol (2007) 1.08
Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys (2008) 1.07
Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol (2009) 1.06
Predictors of PEG dependence after IMRT±chemotherapy for oropharyngeal cancer. Radiother Oncol (2013) 1.03
The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). Int J Radiat Oncol Biol Phys (2003) 1.03
Weekly dose-volume parameters of mucosa and constrictor muscles predict the use of percutaneous endoscopic gastrostomy during exclusive intensity-modulated radiotherapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys (2010) 1.03
Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC. Radiother Oncol (2008) 1.00
Dose-volume and biological-model based comparison between helical tomotherapy and (inverse-planned) IMAT for prostate tumours. Radiother Oncol (2008) 1.00
Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys (2005) 0.98
Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. Int J Radiat Oncol Biol Phys (2008) 0.96
Agreement criteria between expected and measured field fluences in IMRT of head and neck cancer: the importance and use of the gamma histograms statistical analysis. Radiother Oncol (2007) 0.96
Dosimetric predictors of laryngeal edema. Int J Radiat Oncol Biol Phys (2007) 0.96
Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res (2003) 0.96
TomoDirect: an efficient means to deliver radiation at static angles with tomotherapy. Tumori (2011) 0.95
Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study. Radiat Oncol (2012) 0.95
A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol (2009) 0.95
Multipeptide vaccination in cancer patients. Expert Opin Biol Ther (2009) 0.94
Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding window techniques. Radiother Oncol (2005) 0.94
Malignant melanoma. Crit Rev Oncol Hematol (2003) 0.94
Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison. Radiother Oncol (2010) 0.93
miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal (2013) 0.92
A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer. Radiother Oncol (2010) 0.92
Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med (2010) 0.92
Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys (2010) 0.91
Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys (2009) 0.90
Accessibility as a major determinant of radiotherapy underutilization: a population based study. Health Policy (2006) 0.90
Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol (2010) 0.90
Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys (2013) 0.90
In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). Int J Radiat Oncol Biol Phys (2005) 0.90
Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol (2012) 0.89
NTCP modeling of subacute/late laryngeal edema scored by fiberoptic examination. Int J Radiat Oncol Biol Phys (2009) 0.89
Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Med Oncol (2013) 0.89
Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori (2009) 0.88
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol (2003) 0.88
Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus. Tumori (2013) 0.88
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Cancer Immunol Immunother (2008) 0.87
Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. J Oncol Pract (2011) 0.87
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol (2015) 0.87
Laparotomy wound recurrence of endometrial carcinoma. Gynecol Oncol (2003) 0.87
Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. Int J Radiat Oncol Biol Phys (2002) 0.87
Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys (2011) 0.87
PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. Strahlenther Onkol (2011) 0.86
Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. Cancer (2009) 0.86
Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys (2010) 0.86
Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology (2009) 0.85
Modeling set-up error by daily MVCT for prostate adjuvant treatment delivered in 20 fractions: Implications for the assessment of the optimal correction strategies. Radiother Oncol (2009) 0.85
Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. Radiother Oncol (2011) 0.85
Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer. Radiother Oncol (2003) 0.85
Predictive models of toxicity in external radiotherapy: dosimetric issues. Cancer (2009) 0.85
Vaccination therapy in prostate cancer. Cancer Immunol Immunother (2006) 0.85
Chondrosarcoma of the nasal septum. Eur Arch Otorhinolaryngol (2014) 0.84
Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor. Int J Radiat Oncol Biol Phys (2013) 0.84
Texture analysis for the assessment of structural changes in parotid glands induced by radiotherapy. Radiother Oncol (2013) 0.84
Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: A comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy. Radiother Oncol (2009) 0.84
External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy (2009) 0.83
Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2008) 0.83
Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiother Oncol (2012) 0.83
Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors. Radiother Oncol (2011) 0.83